Abbott Laboratories (NYSE:ABT) Upgraded to Buy from Hold

Abbott Laboratories (NYSE:ABT) received an upgrade by equity research analysts at Jefferies & Co Monday morning from Hold to Buy.


Jefferies & Co also set a USD55.000 target price per share on Abbot Laboratories (NYSE:ABT)’s stock.

Out of 17 analysts covering Abbott Laboratories (NYSE:ABT), 16 rate it “Buy”, 0 “Sell”, while 6 “Hold”.

This means 73% are positive. $58 is the highest target while $46 is the lowest. The $50.97 average target is 16.18% above today’s ($45.3) stock price.

Abott Laboratories (NYSE:ABT) closed at 45.30 a share last Friday, a 2.60 percent gain from the previous close. The stock has a 52-week high of 51.74, which was achieved on June 23, 2015. Its 52-week low of 39.00 was posted on September 28, 2015.

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products.

Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. –